Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Xphozah Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Xphozah Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial coverage of Xphozah (tenapanor hydrochloride tablets) for eligible patients through the Boeing client formulary, including prior authorization requirements and quantity limits.

    Policy Summary
    PayerPrime Therapeutics
    PolicyXphozah Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the covered indication, specialist involvement or consultation, and no FDA-labeled contraindication to Xphozah.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20 mg, 30 mgCovered strengths
    60/30 daysQuantity limit
    12 monthsApproval duration
    5.5 mg/dLMinimum phosphorus
    Ferric citrate

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred agent

    Coverage Criteria

    Initial Xphozah Approval

    Target agent approval requires ALL of the following.

    General approval requirements

    • Covered indication pathway

      • CKD dialysis pathway

        • Prerequisite-agent requirement: The patient tried and had an inadequate response to one prerequisite agent; or has an intolerance or hypersensitivity to one prerequisite agent; or has an FDA-labeled contraindication to all prerequisite agents.
        • Preferred-agent requirement when applicable: If the client has preferred agents, the patient tried and had an inadequate response to one preferred agent; or has an intolerance or hypersensitivity to one preferred agent; or has an FDA-labeled contraindication to all preferred agents.

          Preferred agent identified in the policy: ferric citrate.

        • Phosphate-binder requirement: The patient will use phosphate-binder therapy in combination with the requested agent, or has an intolerance, hypersensitivity, or FDA-labeled contraindication to phosphate-binder therapy.
      • Other FDA-labeled indication pathway: The patient has another FDA-labeled indication for the requested agent and route of administration, and the patient's age is within FDA labeling or there is support for use at the patient's age for that indication.
    • Prescriber specialty: The prescriber is a specialist in the area of the patient's diagnosis, such as a nephrologist, or has consulted with a specialist.
    • Contraindication review: The patient does not have any FDA-labeled contraindications to the requested agent.none

    Quantity-Limit Approval

    The quantity limit is approved when ONE of the following is met.

    Quantity-limit criteria

    • Within program limit: The requested quantity or dose does not exceed the program quantity limit.
    • Higher-dose exception: The requested quantity exceeds the program limit and there is support for therapy with a higher dose for the requested indication.
    • Alternative-strength exception: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication and there is support explaining why the requested quantity cannot be achieved with a lower quantity of a higher-strength product that remains within the program quantity limit.not above maximum FDA-labeled dose

    Coverage is excluded when the patient has any FDA-labeled contraindication to Xphozah (tenapanor).

    Clinical and Laboratory Requirements

    Baseline phosphorus
    Minimum levelAt least 5.5 mg/dL
    Measurement timingBaseline phosphorus level measured before therapy with the requested agent
    Applicable pathwayChronic kidney disease with dialysis

    Provider Requirements and Decision Points

    Prior Authorization

    Prior Authorization Required

    Submit a prior authorization request with documentation showing that all applicable clinical criteria are met. Approval may be granted for 12 months; if a quantity limit applies, the quantity-limit criteria must also be satisfied.

    • Include the requested agent, indication, dose, quantity, and supporting clinical documentation.
    • Approval duration: 12 months.
    Step Therapy

    Prerequisite and Preferred-Agent Therapy

    Document use of prerequisite therapy and, when applicable, preferred-agent therapy before requesting Xphozah. The patient must have tried and had an inadequate response, or have an intolerance, hypersensitivity, or FDA-labeled contraindication as specified below.

    • Prerequisite agents include calcium carbonate, calcium acetate, calcium with magnesium, lanthanum carbonate, sevelamer carbonate, and sevelamer HCl.
    • If preferred agents apply, the preferred agent is ferric citrate; document inadequate response, intolerance, hypersensitivity, or an FDA-labeled contraindication to all preferred agents.

    Policy Background

    Xphozah (tenapanor) is reviewed for patients with chronic kidney disease and elevated phosphorus who meet the policy’s dialysis and laboratory requirements, as well as for other FDA-labeled indications. For the CKD pathway, the patient must be receiving dialysis and have a baseline phosphorus level of at least 5.5 mg/dL before therapy. Coverage also requires the applicable prerequisite-agent, preferred-agent, and phosphate-binder criteria, with specialist involvement or consultation and no FDA-labeled contraindication.

    Defined Clinical Pathway

    CKD dialysis pathway
    DiagnosisChronic kidney disease (CKD)
    Dialysis statusThe patient is receiving dialysis
    Baseline phosphorusMeasured before therapy with the requested agent and at least 5.5 mg/dL
    Additional requirementsApplicable prerequisite-agent, preferred-agent, and phosphate-binder requirements must also be satisfied

    Initial Therapy

    Initial Therapy

    Initial Xphozah therapy is approved when all applicable clinical requirements are met.

    Initial therapy requirements: The patient meets a covered indication, applicable prerequisite and preferred-agent requirements, specialist-prescriber requirement, age requirement when applicable, and contraindication review.

    Approval length is 12 months.

    Prerequisite and Preferred-Agent Therapy

    StepPrerequisite-agent requirementPreferred-agent requirement (when applicable)
    1For the CKD dialysis pathway, the patient must have tried and had an inadequate response to one prerequisite agent; or have an intolerance or hypersensitivity to one prerequisite agent; or have an FDA-labeled contraindication to all prerequisite agents. Prerequisite agents include calcium carbonate, calcium acetate, calcium with magnesium, lanthanum carbonate, sevelamer carbonate, and sevelamer HCl. Client-specific prerequisite agents may also apply.If the client has preferred agents, the patient must have tried and had an inadequate response to one preferred agent; or have an intolerance or hypersensitivity to one preferred agent; or have an FDA-labeled contraindication to all preferred agents. Ferric citrate is the preferred agent identified in the policy.

    Quantity Limits

    Quantity limit
    AgentXphozah (tenapanor HCl tablet)
    Strength20 mg
    Quantity limit60 tablets per 30 days
    Quantity limit
    AgentXphozah (tenapanor HCl tablet)
    Strength30 mg
    Quantity limit60 tablets per 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyXphozah Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the covered indication, specialist involvement or consultation, and no FDA-labeled contraindication to Xphozah.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Laboratory RequirementsProvider Requirements and Decision PointsPolicy BackgroundDefined Clinical PathwayInitial TherapyPrerequisite and Preferred-Agent TherapyQuantity Limits
    Above-label-dose exception:
    The requested quantity exceeds the maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.
    above maximum FDA-labeled dose
  1. For CKD use, document phosphate-binder combination therapy or an intolerance, hypersensitivity, or FDA-labeled contraindication to phosphate-binder therapy.
  2. Documentation Required

    Clinical History and Laboratory Documentation

    Provide the patient's relevant clinical history and laboratory results supporting the requested indication. For CKD, documentation must establish dialysis status, the baseline phosphorus level before Xphozah, and the patient's response or intolerance to prerequisite therapy.

    • Document a diagnosis of chronic kidney disease when requesting the CKD indication.
    • Document that the patient is on dialysis.
    • Submit a baseline, pre-treatment phosphorus level of at least 5.5 mg/dL.
    • Document an inadequate response, intolerance, hypersensitivity, or applicable FDA-labeled contraindication involving the required prerequisite agent(s).
    Documentation Required

    Indication, Age, and Prescriber Documentation

    Document the FDA-labeled indication and route of administration, the patient's age eligibility or clinical rationale for use at that age, and the prescriber's qualifications. The prescriber must be a specialist in the area of the diagnosis or have consulted with one.

    • Provide the FDA-labeled indication for the requested agent and route of administration.
    • If the patient's age is outside the FDA labeling for the indication, provide clinical support for use at that age.
    • Document that the prescriber is a specialist, such as a nephrologist, or has consulted with an appropriate specialist.
    • Confirm that the patient has no FDA-labeled contraindications to the requested agent.
    Prior Authorization

    Quantity-Limit Exception Documentation

    When the requested dose or quantity exceeds the program quantity limit, submit documentation supporting the exception. The request must address the requested indication, the maximum FDA-labeled dose, and why the requested quantity is medically necessary.

    • Provide support for therapy with a higher dose for the requested indication when applicable.
    • If the requested quantity does not exceed the maximum FDA-labeled dose, explain why the dose cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose, provide support for therapy above the maximum labeled dose.
    • Quantity-limit exception approval may be granted for 12 months.
    Denial Risk

    General Authorization Requirements Not Met

    The request may be denied when general authorization requirements are not met. Denial conditions include lack of an FDA-labeled indication, unsupported age use, failure to meet prescriber or specialist requirements, an FDA-labeled contraindication, or failure to provide required documentation.

    • No applicable FDA-labeled indication or route of administration is documented.
    • The patient's age is outside FDA labeling and no clinical support is provided.
    • The prescriber is not an appropriate specialist and has not consulted with one.
    • The patient has an FDA-labeled contraindication to the requested agent.
    • Required clinical history, laboratory results, or therapy documentation is missing.
    Denial Risk

    CKD Clinical Criteria Not Met

    The CKD indication may be denied when the required clinical criteria are not established. Documentation must support dialysis, a baseline phosphorus level of at least 5.5 mg/dL, prerequisite-agent therapy, and any applicable preferred-agent or phosphate-binder requirements.

    • The patient does not have documented CKD or is not on dialysis.
    • The baseline, pre-treatment phosphorus level is below 5.5 mg/dL or is not provided.
    • The patient has not tried a required prerequisite agent, or no qualifying inadequate response, intolerance, hypersensitivity, or contraindication is documented.
    • Applicable preferred-agent requirements are not met.
    • The patient will not use phosphate-binder therapy in combination with Xphozah and no qualifying intolerance, hypersensitivity, or FDA-labeled contraindication is documented.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A quantity-limit exception may be denied when the requested quantity exceeds the program limit and the supporting rationale is inadequate. The request must document the requested indication and satisfy the applicable higher-dose, maximum-dose, or lower-quantity rationale.

    • The requested quantity exceeds the program limit without support for higher-dose therapy.
    • The requested quantity is at or below the maximum FDA-labeled dose, but no explanation is provided for why a lower quantity of a higher strength cannot be used within the program limit.
    • The requested quantity exceeds the maximum FDA-labeled dose without support for therapy above the maximum labeled dose.
    • The requested quantity or dose is not adequately justified for the requested indication.